274901-16-5 | Vildagliptin

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$11.00	$8.00
100mg	98%	in stock	$13.00	$9.00
250mg	98%	in stock	$16.00	$11.00
1g	98%	in stock	$17.00	$12.00
5g	98%	in stock	$39.00	$28.00
10g	98%	in stock	$66.00	$46.00
25g	98%	in stock	$128.00	$90.00
100g	98%	in stock	$371.00	$260.00
500g	98%	in stock	$1,401.00	$981.00

Description

• Catalog Number: AB31876
• Chemical Name: Vildagliptin
• CAS Number: 274901-16-5
• Molecular Formula: C17H25N3O2
• Molecular Weight: 303.3993
• MDL Number: MFCD31630807
• SMILES: N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(C1)CC(C2)(C3)O

Computed Properties

• Complexity: 523
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• Undefined Atom Stereocenter Count: 2
• XLogP3: 0.9

Literature

• SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.

  Toxicology and applied pharmacology 20171015

• A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

  European journal of pharmacology 20121205

• Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201

• One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.

  Diabetes, obesity & metabolism 20121101

• Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

  Journal of clinical pharmacology 20121001

• Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

  Diabetes care 20121001

• Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

  Diabetes technology & therapeutics 20121001

• Recent advances in incretin-based therapies.

  Clinical endocrinology 20121001

• Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

  Diabetes & metabolism 20121001

• DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.

  Journal of molecular endocrinology 20121001

• Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

  The Journal of clinical endocrinology and metabolism 20121001

• Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.

  Bioorganic & medicinal chemistry 20121001

• Linagliptin as add-on therapy for type 2 diabetes - an overview.

  Drugs of today (Barcelona, Spain : 1998) 20121001

• Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120929

• Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

  European journal of pharmacology 20120915

• Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

  World journal of diabetes 20120915

• DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

  American journal of physiology. Renal physiology 20120901

• Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.

  Peptides 20120901

• The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.

  Journal of clinical pharmacy and therapeutics 20120801

• Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20120801

• GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

  Current clinical pharmacology 20120801

• Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.

  Endocrinology 20120801

• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  Clinical pharmacokinetics 20120801

• Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models.

  Acta pharmacologica Sinica 20120801

• Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.

  Metabolism: clinical and experimental 20120701

• The incretin hormones: from scientific discovery to practical therapeutics.

  Diabetologia 20120701

• Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.

  International journal of cardiology 20120628

• Nutrient detection by incretin hormone secreting cells.

  Physiology & behavior 20120606

• Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

  Journal of diabetes 20120601

• Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

  Expert opinion on pharmacotherapy 20120601

• Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.

  Diabetes technology & therapeutics 20120601

• Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

  Clinical therapeutics 20120601

• Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

  Bioorganic & medicinal chemistry letters 20120515

• CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.

  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 20120501

• An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

  Current diabetes reviews 20120501

• High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501

• Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product.

  Journal of chromatographic science 20120501

• Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  Diabetes & metabolism 20120401

• Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

  Diabetes technology & therapeutics 20120401

• Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.

  Diabetes, obesity & metabolism 20120401

• Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

  Diabetes, obesity & metabolism 20120401

• Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.

  International journal of clinical pharmacology and therapeutics 20120401

• Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.

  Endocrinology 20120301

• Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20120301

• Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

  Clinical pharmacokinetics 20120301

• Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.

  Minerva endocrinologica 20120301

• Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

  British journal of clinical pharmacology 20120301

• Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

  British journal of clinical pharmacology 20120301

• Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus.

  Indian journal of endocrinology and metabolism 20120301

• Pleiotropic effects of incretins.

  Indian journal of endocrinology and metabolism 20120301

• Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

  Protein and peptide letters 20120201

• Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.

  The Journal of pharmacology and experimental therapeutics 20120101

• Diabetes: impaired damage control.

  Diabetologia 20120101

• A review of gliptins in 2011.

  Expert opinion on pharmacotherapy 20120101

• DPP-4 inhibitors and lipids: systematic review and meta-analysis.

  Advances in therapy 20120101

• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

  Cardiovascular diabetology 20120101

• Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

  Cardiovascular diabetology 20120101

• Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

  Gut and liver 20120101

• Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.

  BMC gastroenterology 20120101

• Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

  BMC pharmacology 20120101

• Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.

  PloS one 20120101

• Uncovering undetected hypoglycemic events.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

  Experimental diabetes research 20120101

• Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

  ISRN endocrinology 20120101

• Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.

  Journal of diabetes and its complications 20120101

• Red carpeting the newer antidiabetics.

  Journal of pharmacology & pharmacotherapeutics 20120101

• The management of type 2 diabetic patients with hypoglycaemic agents.

  ISRN endocrinology 20120101

• Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20120101

• Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.

  Vascular health and risk management 20120101

• Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.

  Cardiovascular diabetology 20120101

• Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

  Cardiovascular diabetology 20120101

• Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.

  PloS one 20120101

• Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.

  Internal medicine (Tokyo, Japan) 20120101

• Impact of diabetes on postinfarction heart failure and left ventricular remodeling.

  Current heart failure reports 20111201

• [Incretin-based therapy for treating patients with type 2 diabetes].

  Orvosi hetilap 20111127

• Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

  Xenobiotica; the fate of foreign compounds in biological systems 20111101

• The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

  International journal of clinical practice 20111101

• Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

  Clinical therapeutics 20111101

• Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.

  Current medical research and opinion 20111101

• Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.

  The Journal of the Association of Physicians of India 20111101

• Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.

  Diabetes, obesity & metabolism 20111001

• Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.

  Diabetologia 20111001

• Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.

  Diabetes & metabolism journal 20111001

• 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.

  Bioorganic & medicinal chemistry 20110915

• [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

  Orvosi hetilap 20110911

• Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.

  Diabetes, obesity & metabolism 20110901

• The metabolic syndrome influences the response to incretin-based therapies.

  Acta diabetologica 20110901

• Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.

  Diabetes care 20110901

• Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.

  Recent patents on endocrine, metabolic & immune drug discovery 20110901

• Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.

  Current diabetes reviews 20110901

• Emerging role of insulin with incretin therapies for management of type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

• Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

  Journal of medicinal chemistry 20110825

• Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

  Diabetologia 20110801

• Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.

  Diabetologia 20110801

• Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions.

  Clinical & experimental metastasis 20110801

• Vildagliptin in the treatment of type 2 diabetes mellitus.

  Expert opinion on pharmacotherapy 20110801

• Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.

  Expert opinion on drug discovery 20110801

• Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

  Drugs 20110730

• Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

  Diabetes, obesity & metabolism 20110701

• Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.

  Current medical research and opinion 20110701

• Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.

  Current medical research and opinion 20110701

• Noninsulin pharmacological management of type 1 diabetes mellitus.

  Indian journal of endocrinology and metabolism 20110701

• Health economic evaluation of dipeptidyl peptidase-4 inhibitors.

  Indian journal of endocrinology and metabolism 20110701

• Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea.

  Arquivos brasileiros de endocrinologia e metabologia 20110601

• An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

  Contemporary clinical trials 20110501

• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.

  Pharmacological research 20110501

• Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.

  Diabetes 20110501

• DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

  Diabetes care 20110501

• [Vildagliptin].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

  Clinical therapeutics 20110501

• Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501

• Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501

• Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.

  Journal of medicinal chemistry 20110414

• Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

  Diabetes, obesity & metabolism 20110401

• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110401

• Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as 'isoglycemic' intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20110401

• Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.

  Analytical and bioanalytical chemistry 20110401

• GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.

  Diabetes 20110401

• Understanding the incretin effect.

  The Journal of clinical endocrinology and metabolism 20110401

• [Incretin therapy and the metabolic syndrome].

  Vnitrni lekarstvi 20110401

• Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.

  Diabetes & metabolism journal 20110401

• Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.

  Diabetes & metabolism journal 20110401

• Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

  The Journal of the Association of Physicians of India 20110401

• Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.

  Journal of medicinal chemistry 20110324

• Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.

  Diabetes, obesity & metabolism 20110301

• Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.

  Diabetes, obesity & metabolism 20110301

• Type 2 diabetes: uses of thiazolidinediones and insulin.

  Diabetes care 20110201

• Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.

  Diabetes care 20110201

• Alogliptin for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20110201

• Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

  Hospital practice (1995) 20110201

• Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

  Prescrire international 20110201

• The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.

  European journal of pharmacology 20110115

• The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.

  European journal of pharmacology 20110110

• Advances in the treatment of type 2 diabetes mellitus.

  American journal of therapeutics 20110101

• Weight considerations in pharmacotherapy for type 2 diabetes.

  Journal of obesity 20110101

• Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials.

  Diabetes, obesity & metabolism 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

  Cardiovascular diabetology 20110101

• Vildagliptin-induced acute pancreatitis.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations' by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83).

  Journal of diabetes and its complications 20110101

• Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.

  Vascular health and risk management 20110101

• Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.

  Journal of medical case reports 20110101

• [Plasmapheresis as treatment for severe hypertriglyceridemia].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110101

• Sensing via intestinal sweet taste pathways.

  Frontiers in neuroscience 20110101

• Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.

  PloS one 20110101

• Incretin-based therapy and pancreatitis-what is the risk?

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Diabetes and Ramadan: an update on use of glycemic therapies during fasting.

  Annals of Saudi medicine 20110101

• Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.

  Indian journal of endocrinology and metabolism 20110101

• Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.

  Cardiovascular diabetology 20110101

• Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.

  Experimental diabetes research 20110101

• From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

  Experimental diabetes research 20110101

• New onset diabetes after transplantation (NODAT): an overview.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

  The open cardiovascular medicine journal 20110101

• Reply to the 'Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'', by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353).

  Journal of diabetes and its complications 20110101

• Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and GIPR(dn) transgenic diabetic mice.

  PloS one 20110101

• Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

  Clinical drug investigation 20110101

• Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.

  Experimental diabetes research 20110101

• The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

  Endocrine journal 20110101

• Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

  Cardiovascular diabetology 20110101

• Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

  The open medicinal chemistry journal 20110101

• Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

  Journal of pharmacology & pharmacotherapeutics 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Choosing a gliptin.

  Indian journal of endocrinology and metabolism 20110101

• Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

  Open medicine : a peer-reviewed, independent, open-access journal 20110101

• Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

  PloS one 20110101

• Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

  Cardiovascular diabetology 20110101

• Molecular determinants of magnolol targeting both RXRα and PPARγ.

  PloS one 20110101

• [Characterization of patients with type 2 diabetes treated with vildagliptin].

  Acta medica portuguesa 20110101

• A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20101203

• Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study.

  Diabetes care 20101201

• Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.

  Korean diabetes journal 20101201

• Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

  Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201

• Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes.

  World journal of diabetes 20101115

• Vildagliptin: a review of its use in type 2 diabetes mellitus.

  Drugs 20101112

• Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.

  Diabetes research and clinical practice 20101101

• DPP-4 inhibitors: what may be the clinical differentiators?

  Diabetes research and clinical practice 20101101

• Multidrug therapy in a patient with Rabson-Mendenhall syndrome.

  Diabetologia 20101101

• Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

  Diabetes care 20101101

• Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.

  Current diabetes reviews 20101101

• [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20101101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101101

• SLCO1B1 polymorphism and oral antidiabetic drugs.

  Basic & clinical pharmacology & toxicology 20101001

• Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.

  Diabetologia 20101001

• Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.

  Diabetes 20101001

• Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

  Expert opinion on drug metabolism & toxicology 20101001

• Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20101001

• Liraglutide: effects beyond glycaemic control in diabetes treatment.

  International journal of clinical practice. Supplement 20101001

• Sitagliptin-induced hemolysis.

  Indian journal of pharmacology 20101001

• Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

  The American journal of geriatric pharmacotherapy 20101001

• Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.

  Journal of medicinal chemistry 20100923

• Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.

  Diabetes research and clinical practice 20100901

• Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100901

• Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.

  Diabetes, obesity & metabolism 20100901

• Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

  Clinical pharmacokinetics 20100901

• Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.

  Diabetes care 20100901

• Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

  International journal of clinical pharmacology and therapeutics 20100901

• [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].

  Medicina clinica 20100901

• The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis.

  Diabetes care 20100801

• Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100801

• Managing type 2 diabetes in the primary care setting: beyond glucocentricity.

  The American journal of the medical sciences 20100801

• Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

  Diabetes, obesity & metabolism 20100801

• Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.

  Diabetes, obesity & metabolism 20100801

• Recommendations for management of diabetes during Ramadan: update 2010.

  Diabetes care 20100801

• Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.

  Indian journal of pharmacology 20100801

• The evolving place of incretin-based therapies in type 2 diabetes.

  Pediatric nephrology (Berlin, Germany) 20100701

• Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

  Diabetologia 20100701

• Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.

  Current medical research and opinion 20100701

• Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

  Arteriosclerosis, thrombosis, and vascular biology 20100701

• Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?

  Diabetes 20100701

• Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

  British journal of clinical pharmacology 20100701

• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100701

• (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

  Bioorganic & medicinal chemistry letters 20100615

• Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry letters 20100615

• Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry letters 20100615

• Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses.

  Cell metabolism 20100609

• Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

  International journal of clinical practice 20100601

• Diabesity: therapeutic options.

  Diabetes, obesity & metabolism 20100601

• Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.

  Diabetes, obesity & metabolism 20100601

• An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.

  Diabetes, obesity & metabolism 20100601

• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.

  Pharmacotherapy 20100501

• Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.

  Diabetes, obesity & metabolism 20100501

• Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

  Diabetes 20100501

• Graphic rule for drug metabolism systems.

  Current drug metabolism 20100501

• [New hypoglycemic agents in type 2 diabetes].

  La Revue du praticien 20100420

• Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

  Diabetes care 20100401

• Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

  Diabetes 20100401

• Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

  Diabetes, obesity & metabolism 20100401

• Effect of vildagliptin as add-on therapy to a low-dose metformin.

  World journal of diabetes 20100315

• ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.

  Acta diabetologica 20100301

• [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

  Pharmazie in unserer Zeit 20100301

• A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

  Diabetic medicine : a journal of the British Diabetic Association 20100301

• Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.

  Regulatory peptides 20100225

• Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.

  ChemMedChem 20100201

• Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

  Diabetes care 20100201

• Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.

  Journal of medicinal chemistry 20100128

• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  Journal of diabetes and its complications 20100101

• The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.

  Diabetes technology & therapeutics 20100101

• Clinical approaches to preserve beta-cell function in diabetes.

  Advances in experimental medicine and biology 20100101

• [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

  Nederlands tijdschrift voor geneeskunde 20100101

• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

  BMC endocrine disorders 20100101

• Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.

  Vascular health and risk management 20100101

• Rhinorrhea, cough and fatigue in patients taking sitagliptin.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20100101

• Forecasting drug utilization and expenditure in a metropolitan health region.

  BMC health services research 20100101

• Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.

  Therapeutics and clinical risk management 20100101

• Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

  BMC health services research 20100101

• Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society.

  Diabetology & metabolic syndrome 20100101

• A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

  Pharmacology 20100101

• Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment--Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial.

  BMJ (Clinical research ed.) 20100101

• Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.

  Vascular health and risk management 20100101

• Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.

  PloS one 20100101

• Exenatide once weekly: clinical outcomes and patient satisfaction.

  Patient preference and adherence 20100101

• Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

  Vascular health and risk management 20100101

• A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.

  Trials 20100101

• Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20100101

• Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

  PloS one 20100101

• [The incretin effect and type 2 diabetes].

  Revista medica del Instituto Mexicano del Seguro Social 20100101

• Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Optimizing weight control in diabetes: antidiabetic drug selection.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Saxagliptin for type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.

  Drug, healthcare and patient safety 20100101

• Managing insulin resistance: role of liraglutide.

  Clinical pharmacology : advances and applications 20100101

• Reporting of results of interventional studies by the information service of the National Institutes of Health.

  Clinical pharmacology : advances and applications 20100101

• Exercise therapy in type 2 diabetes.

  Acta diabetologica 20091201

• Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091201

• Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

  European journal of endocrinology 20091201

• Vildagliptin in clinical practice: a review of literature.

  Expert opinion on pharmacotherapy 20091101

• Incretin-based therapies: viewpoints on the way to consensus.

  Diabetes care 20091101

• Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.

  Diabetes care 20091101

• Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

  Diabetes care 20091101

• Obesity in the elderly diabetic patient: is weight loss beneficial? No.

  Diabetes care 20091101

• DPP-4 inhibitors in clinical practice.

  Postgraduate medicine 20091101

• A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20091101

• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

  Pharmacology & therapeutics 20091001

• Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

  Diabetes, obesity & metabolism 20091001

• Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

  International journal of clinical practice 20091001

• Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.

  Archives of medical research 20091001

• Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

  Clinical science (London, England : 1979) 20090928

• Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

  The Journal of biological chemistry 20090911

• The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

  Diabetes care 20090901

• Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

  Diabetes 20090901

• Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

  Hypertension (Dallas, Tex. : 1979) 20090901

• Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.

  Hypertension (Dallas, Tex. : 1979) 20090901

• The 6th Annual World Congress on the insulin resistance syndrome.

  Diabetes care 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.

  European journal of medicinal chemistry 20090801

• Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

  Diabetes, obesity & metabolism 20090801

• Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Functional assessment of pancreatic beta-cell area in humans.

  Diabetes 20090701

• Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

  European journal of internal medicine 20090701

• Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

  Diabetes 20090601

• Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090601

• Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

  The American journal of medicine 20090601

• Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

  Diabetes, obesity & metabolism 20090601

• [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].

  Journal de pharmacie de Belgique 20090601

• Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090501

• Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090501

• Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.

  Current medical research and opinion 20090501

• Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20090501

• The scientific evidence: vildagliptin and the benefits of islet enhancement.

  Diabetes, obesity & metabolism 20090501

• Translating science into clinical practice: focus on vildagliptin in combination with metformin.

  Diabetes, obesity & metabolism 20090501

• [The value of incretin based therapies].

  Deutsche medizinische Wochenschrift (1946) 20090501

• [Incretin related agents for treatment of diabetes mellitus].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410

• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20090401

• Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20090401

• Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

  Diabetes 20090401

• Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry 20090315

• New treatments in type 2 diabetes: a focus on the incretin-based therapies.

  Clinical endocrinology 20090301

• Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.

  The Journal of clinical endocrinology and metabolism 20090301

• Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.

  Metabolism: clinical and experimental 20090301

• Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry 20090301

• Diabetes treatment.

  Diabetes care 20090301

• Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Advances in therapy 20090301

• [Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes].

  Revue medicale de Liege 20090301

• Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models.

  The Journal of pharmacology and experimental therapeutics 20090201

• Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20090201

• Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

  Diabetes, obesity & metabolism 20090201

• Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

  Current drug metabolism 20090201

• Drug evaluation: vildagliptin-metformin single-tablet combination.

  Advances in therapy 20090201

• In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.

  Biochemical pharmacology 20090115

• Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.

  Journal of clinical pharmacology 20090101

• Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

  Diabetes 20090101

• Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.

  Diabetes care 20090101

• Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

  Diabetes care 20090101

• Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20090101

• Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

  Current drug targets 20090101

• Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.

  Postgraduate medicine 20090101

• Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.

  Postgraduate medicine 20090101

• Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

  Mymensingh medical journal : MMJ 20090101

• Postprandial hyperglycemia as an etiological factor in vascular failure.

  Cardiovascular diabetology 20090101

• Potential of liraglutide in the treatment of patients with type 2 diabetes.

  Vascular health and risk management 20090101

• Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.

  PloS one 20090101

• A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

  Cardiovascular diabetology 20090101

• Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

  Therapeutics and clinical risk management 20090101

• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  Journal of the American Pharmacists Association : JAPhA 20090101

• Diabetic nephropathy.

  Diabetology & metabolic syndrome 20090101

• Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.

  Pharmacological reports : PR 20090101

• Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

  Journal of diabetes science and technology 20090101

• Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.

  International journal of clinical practice 20090101

• Gliptins: a new class of oral antidiabetic agents.

  Indian journal of pharmaceutical sciences 20090101

• Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Alogliptin: a new addition to the class of DPP-4 inhibitors.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• DPP4 inhibitors for diabetes--what next?

  Biochemical pharmacology 20081215

• Incretin-based therapies in type 2 diabetes: a review of clinical results.

  Diabetes research and clinical practice 20081215

• Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081201

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

  Diabetes care 20081201

• Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.

  Expert opinion on emerging drugs 20081201

• Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.

  Acta bio-medica : Atenei Parmensis 20081201

• Gateways to clinical trials. December 2008.

  Methods and findings in experimental and clinical pharmacology 20081201

• Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

  Vascular health and risk management 20081201

• Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

  Vascular health and risk management 20081201

• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

  Diabetes, obesity & metabolism 20081101

• The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

  Clinical endocrinology 20081101

• Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

  Diabetes, obesity & metabolism 20081101

• Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.

  Diabetes, obesity & metabolism 20081101

• Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

  Cardiology clinics 20081101

• The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.

  Current diabetes reviews 20081101

• [Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].

  MMW Fortschritte der Medizin 20081030

• Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081001

• Incretin-based therapies in type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20081001

• [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].

  Deutsche medizinische Wochenschrift (1946) 20081001

• Recent advances in the management of type 2 diabetes mellitus: a review.

  Postgraduate medical journal 20081001

• Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.

  Prescrire international 20081001

• Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

  Diabetes, obesity & metabolism 20080901

• Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

  Diabetes, obesity & metabolism 20080801

• Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

  Arquivos brasileiros de endocrinologia e metabologia 20080801

• RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20080801

• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

  Vascular health and risk management 20080801

• Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.

  Bioorganic & medicinal chemistry letters 20080715

• Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors.

  Bioorganic & medicinal chemistry letters 20080715

• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

  Current opinion in clinical nutrition and metabolic care 20080701

• Beyond insulin replacement: addressing the additional needs of the diabetes patient.

  Diabetes, obesity & metabolism 20080701

• From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.

  Current opinion in drug discovery & development 20080701

• Three new drugs for type 2 diabetes.

  Drug and therapeutics bulletin 20080701

• DPP4 inhibitors: a new approach in diabetes treatment.

  Advances in therapy 20080701

• Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

  International journal of clinical pharmacology and therapeutics 20080701

• Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080601

• Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.

  Current medical research and opinion 20080601

• Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

  Expert opinion on investigational drugs 20080601

• Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.

  The AAPS journal 20080601

• Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.

  Vascular health and risk management 20080601

• Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20080601

• Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?

  Naunyn-Schmiedeberg's archives of pharmacology 20080501

• Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

  Frontiers in bioscience : a journal and virtual library 20080501

• Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20080501

• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20080416

• (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

  The Journal of pharmacology and experimental therapeutics 20080401

• Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.

  Diabetic medicine : a journal of the British Diabetic Association 20080401

• Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

  Vascular health and risk management 20080401

• The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

  British journal of clinical pharmacology 20080301

• Hypoglycaemia in Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20080301

• Islet cell function is as interesting as insulin resistance for T2DM treatment options.

  International journal of clinical practice. Supplement 20080301

• The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

  International journal of clinical practice. Supplement 20080301

• Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

  International journal of clinical practice. Supplement 20080301

• Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20080201

• Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.

  Diabetes & metabolism 20080201

• DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?

  Diabetes & metabolism 20080201

• The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

  Diabetes care 20080101

• Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

  The Journal of clinical endocrinology and metabolism 20080101

• Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

  Diabetes care 20080101

• Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

  Journal of clinical pharmacology 20080101

• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

  Diabetes, obesity & metabolism 20080101

• Update: vildagliptin for the treatment of Type 2 diabetes.

  Expert opinion on investigational drugs 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.

  PloS one 20080101

• Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

  Medscape journal of medicine 20080101

• Vaccination against GIP for the treatment of obesity.

  PloS one 20080101

• Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

  The review of diabetic studies : RDS 20080101

• New drugs for type 2 diabetes mellitus: what is their place in therapy?

  Drugs 20080101

• New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

  Drugs & aging 20080101

• Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

  BMC endocrine disorders 20080101

• Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

  Drugs 20080101

• Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.

  Current topics in medicinal chemistry 20080101

• The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.

  Indian journal of pharmacology 20080101

• Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.

  Clinical medicine. Pathology 20080101

• [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].

  Lakartidningen 20071205

• Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

  Diabetes 20071201

• Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.

  Diabetes care 20071201

• Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.

  Current medical research and opinion 20071201

• DPP-4 inhibitors.

  Best practice & research. Clinical endocrinology & metabolism 20071201

• Clinical management strategies for type 2 diabetes.

  JAAPA : official journal of the American Academy of Physician Assistants 20071201

• New treatments for type 2 diabetes--the DPP4 inhibitors.

  Primary care diabetes 20071201

• The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

  The Journal of clinical endocrinology and metabolism 20071101

• Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071101

• DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

  Regulatory peptides 20071004

• GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

  Current diabetes reports 20071001

• Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20070901

• Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

  Journal of clinical pharmacology 20070901

• Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

  Diabetes, obesity & metabolism 20070901

• The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.

  Diabetes, obesity & metabolism 20070901

• Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

  Nature clinical practice. Endocrinology & metabolism 20070801

• Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

  International journal of clinical practice. Supplement 20070801

• Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.

  International journal of clinical practice. Supplement 20070801

• Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.

  International journal of clinical practice. Supplement 20070801

• Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

  Pharmacotherapy 20070801

• Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.

  Journal of clinical pharmacology 20070801

• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  JAMA 20070711

• The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.

  European journal of clinical pharmacology 20070701

• [New concepts in the treatment of type 2 diabetes].

  Der Internist 20070701

• A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

  Current medical research and opinion 20070701

• Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

  Diabetes care 20070601

• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.

  Diabetologia 20070601

• Which patients are candidates for dipeptidyl peptidase IV inhibitors?

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070601

• Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070601

• New treatments for diabetes.

  The New England journal of medicine 20070524

• Dipeptidyl peptidase 8/9-like activity in human leukocytes.

  Journal of leukocyte biology 20070501

• Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

  Diabetes 20070501

• Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

  Journal of clinical pharmacology 20070501

• The role of vildagliptin in the management of type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20070501

• Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

  Current medical research and opinion 20070501

• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  Diabetes research and clinical practice 20070401

• The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

  The Journal of clinical endocrinology and metabolism 20070401

• Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

  Diabetes care 20070401

• beta-cell failure in diabetes and preservation by clinical treatment.

  Endocrine reviews 20070401

• [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].

  Orvosi hetilap 20070401

• Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

  Current medical research and opinion 20070401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].

  Revue medicale de Liege 20070401

• Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

  Vascular health and risk management 20070401

• Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

  Current opinion in endocrinology, diabetes, and obesity 20070401

• 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.

  Bioorganic & medicinal chemistry letters 20070301

• Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.

  Diabetes, obesity & metabolism 20070301

• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

  Diabetes, obesity & metabolism 20070301

• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20070301

• Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20070301

• Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

  Diabetes care 20070201

• Incretins: a new treatment option for type 2 diabetes?

  The Netherlands journal of medicine 20070201

• Gliptins.

  Lancet (London, England) 20070127

• Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

  Diabetes 20070101

• Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.

  Journal of clinical pharmacology 20070101

• The physiology of incretin hormones and the basis for DPP-4 inhibitors.

  The Diabetes educator 20070101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• 11 Years of cyanopyrrolidines as DPP-IV inhibitors.

  Current topics in medicinal chemistry 20070101

• Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain.

  ACP journal club 20070101

• Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

  Clinical pharmacokinetics 20070101

• The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

  Clinical pharmacokinetics 20070101

• Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy.

  ACP journal club 20070101

• Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.

  Journal of endocrinological investigation 20070101

• 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

  The Journal of pharmacology and experimental therapeutics 20061201

• Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

  Diabetes & vascular disease research 20061201

• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  Lancet (London, England) 20061111

• DPP-4 inhibitors and their potential role in the management of type 2 diabetes.

  International journal of clinical practice 20061101

• How do different GLP-1 mimetics differ in their actions?

  Current diabetes reports 20061101

• Exenatide: a novel approach for treatment of type 2 diabetes.

  Southern medical journal 20061101

• Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

  Journal of medicinal chemistry 20061019

• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

  Diabetologia 20060901

• Targeting postprandial hyperglycemia.

  Metabolism: clinical and experimental 20060901

• Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.

  Geriatrics 20060901

• American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20060801

• Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20060801

• Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

  Minerva endocrinologica 20060601

• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20060601

• Molecule of the month. Vildagilptin.

  Drug news & perspectives 20060501

• Diabetes: assessing the pipeline.

  Atherosclerosis. Supplements 20060401

• Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.

  Expert opinion on investigational drugs 20060401

• Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.

  Pediatric diabetes 20060401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060401

• [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].

  Medizinische Monatsschrift fur Pharmazeuten 20060301

• T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

  Modern rheumatology 20060201

• 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

  Journal of medicinal chemistry 20060112

• Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.

  Clinical chemistry 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101

• Vildagliptin.

  Drugs 20060101

• Basic Management of Diabetes Mellitus: Practical guidelines.

  The Libyan journal of medicine 20060101

• Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

  The Journal of pharmacology and experimental therapeutics 20051101

• Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.

  Diabetes, obesity & metabolism 20051101

• Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.

  European journal of pharmacology 20051003

• Incretins: what does the future hold?

  Diabetes technology & therapeutics 20051001

• Alpha cell function in health and disease: influence of glucagon-like peptide-1.

  Diabetologia 20050901

• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20050801

• Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

  Diabetes care 20050801

• American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.

  IDrugs : the investigational drugs journal 20050801

• Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

  Biochemical pharmacology 20050701

• Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.

  Bioorganic & medicinal chemistry letters 20050701

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050301

• Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8.

  Bioorganic & medicinal chemistry letters 20050201

• Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.

  Treatments in endocrinology 20050101

• New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

  The review of diabetic studies : RDS 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041101

• 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20040105

• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  Journal of medicinal chemistry 20030619